Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04436640 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Study acronym: BE MOVING
StatusCompleted
PhasePhase 3
Started2020-06-16
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 103 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-09-07
Study Status, References v102
Trial completed
Publications7 to 9 entries
Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Morup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axia [...]
2026-09-04
Active, Not Recruiting→Completed Study Status v101
Trial statusActive, Not Recruiting→Completed
Primary completion dateestimated 2026-08-07→confirmed 2026-08-09
Completion dateestimated 2026-08-07→confirmed 2026-08-09
2026-08-13
14 amendments v87-v100
14 re-verifications since 2025-12-18, no change to tracked fields
2025-12-04
Study Status, References v86
Publications6 to 7 entries
Ramiro S, Poddubnyy D, Mease PJ, Lopez-Medina C, Kim M, Massow U, Taieb V, Kragstrup TW, McGonagle D. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025 Oct 22;11(4):e005969. doi: 10.1136/rmdopen-2025-005969.
2025-11-20
16 amendments v70-v85
16 re-verifications since 2024-10-24, no change to tracked fields
Show 17 earlier versions
2024-09-12
Study Status, References v69
Publications5 to 6 entries
Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, de Peyrecave N, Vaux T, White K, Deodhar A, van der Horst-Bruinsma I. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis [...]
2024-08-01
7 amendments v62-v68
7 re-verifications since 2023-10-12, no change to tracked fields
2023-09-27
Study Status, Study Design v61
Enrollment targetestimated 485→confirmed 508
2023-09-14
7 amendments v54-v60
7 re-verifications since 2023-05-25, no change to tracked fields
2023-04-13
Study Status, Contacts/Locations v53
Study sites76→75
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
Trial Details
NCT Number NCT04436640
Lead Sponsor UCB Biopharma SRL
Conditions Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Enrollment 508 participants
Start Date 2020-06-16
Primary Completion 2026-08-09 (estimated)
Study Completion 2026-08-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-10